Needham Reiterates Buy on Inari Medical, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson reiterates a Buy rating on Inari Medical (NARI) and maintains a $72 price target.

February 29, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterates a Buy rating on Inari Medical with a $72 price target.
The reiteration of a Buy rating and maintenance of a $72 price target by a reputable analyst like Mike Matson from Needham is likely to instill confidence among investors and could positively influence Inari Medical's stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100